At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 78 enrolled
Drug / intervention
Havrix™biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double-blind, Randomized Study to Evaluate the Immunogenicity and Reactogenicity of Three Different Lots of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Containing 1440 EL.U of Antigen Per mL and Injected According to a 0, 6 Month Schedule in Healthy Adult Subjects
In Brief
A Phase 4 clinical trial evaluating Havrix™ for Hepatitis A. Completed, enrolled 78 participants across 1 site.
Detailed Summary
The aim of this study is to evaluate the long-term persistence of hepatitis A antibodies at 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 years after subjects received their first dose of a 2 dose vaccination schedule of hepatitis A vaccine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis A
CountriesBelgium
Collaborators--
Timeline
Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2004
First PostedFeb 2006
Primary CompletionMar 2013
TodayJul 2026
First PostedFeb 10, 2006
Enrollment StartJan 1, 2004
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 20.4 years ago
Interventions
Havrix™biological
2 doses at 6 months interval